A key aspect of this proposal, embedded in each of the three research projects is the validation of predictions made by computational models of specific cellular programs involve in cancer progression. Those predictions need to be tested in cells and in animals by gain-of-function or loss of-function experiments. RNA interference (RNAi) has emerged as a novel cellular mechanism regulating gene expression at the posttranscriptional level and as a powerful tool to control gene function experimentally There have been several recent advances in the biology and application of RNAi. These include the definition of improved criteria for selecting effective small interfering RNA (siRNA) sequences ; improved methods for delivery of short interfering RNAs (siRNAs) or expression of short hairpin RNAs (shRNAs), which in turn generate siRNAs leading to stable silencing of genes in mammalian cells, tissues, and animals using retroviral expression systems. Both focused and high-throughput screening projects based on RNAi have been initiated to search for genes involved in basic biological processes, as well as in complex pathological conditions associated with cancer. The ICBP RNAi resource will develop new siRNA/shRNA delivery technologies and will provide support to the participants in this program that plan to use RNAi technologies in their research.
The specific aims of the RNAi resource facility are to: 1. Generate and distribute a set of functionally validated siRNAs and shRNAs that are able to silence genes of interest to the ICBP. 2. Develop and improve selection criteria for functional siRNA sequences. 3. Develop new approaches to achieve constitutive, regulated, or tissue-specific delivery of siRNAs and expression of shRNAs. 4. Provide technical and scientific advice to ICBP investigators on how to use RNAi technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA112967-05
Application #
7694421
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
5
Fiscal Year
2008
Total Cost
$427,892
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Kulkarni, Madhura; Tan, Tuan Zea; Syed Sulaiman, Nurfarhanah Bte et al. (2018) RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. Oncotarget 9:14175-14192
Miller, Miles A; Sullivan, Ryan J; Lauffenburger, Douglas A (2017) Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. Clin Cancer Res 23:623-629
Nagel, Zachary D; Kitange, Gaspar J; Gupta, Shiv K et al. (2017) DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer Res 77:198-206
Oudin, Madeleine J; Barbier, Lucie; Schäfer, Claudia et al. (2017) MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. Mol Cancer Ther 16:143-155
Bruno, Peter M; Liu, Yunpeng; Park, Ga Young et al. (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 23:461-471
Werbin, Jeffrey L; Avendaño, Maier S; Becker, Verena et al. (2017) Multiplexed Exchange-PAINT imaging reveals ligand-dependent EGFR and Met interactions in the plasma membrane. Sci Rep 7:12150
White, Forest M; Wolf-Yadlin, Alejandro (2016) Methods for the Analysis of Protein Phosphorylation-Mediated Cellular Signaling Networks. Annu Rev Anal Chem (Palo Alto Calif) 9:295-315
Wilson, Jennifer L; Dalin, Simona; Gosline, Sara et al. (2016) Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia. Integr Biol (Camb) 8:761-74
Zhao, Boyang; Hemann, Michael T; Lauffenburger, Douglas A (2016) Modeling Tumor Clonal Evolution for Drug Combinations Design. Trends Cancer 2:144-158
Tuncbag, Nurcan; Milani, Pamela; Pokorny, Jenny L et al. (2016) Network Modeling Identifies Patient-specific Pathways in Glioblastoma. Sci Rep 6:28668

Showing the most recent 10 out of 222 publications